Hengrui Liang1,2, Zhenkui Pan3, Wei Wang1, Chengye Guo3, Difei Chen1,2, Jianrong Zhang1, Yiyin Zhang1,2, Shiyan Tang1,2, Jianxing He1, Wenhua Liang1. 1. Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China. 2. Nanshan School, Guangzhou Medical University, Guangzhou 511436, China. 3. Department of Oncology, Qingdao Municipal Hospital, Qingdao 266011, China.
Abstract
BACKGROUND: Treatment-naive epidermal growth factor receptor (EGFR) T790M mutation is more inclined to coexist with L858R than with 19 del in non-small cell lung cancer (NSCLC) patients. However, EGFR-tyrosine kinase inhibitors (EGFR-TKIs) might alter this status. We sought to compare the prevalence of T790M upon acquired resistance to EGFR-TKIs between 19 del and L858R by assembling all existing data. METHODS: Electronic databases were comprehensively searched for eligible studies. The primary endpoint was the odds ratio (OR) of T790M mutation in NSCLC co-existing with L858R mutation and 19 del upon resistance to first-generation EGFR-TKIs. A random effects model was used. Stratified analysis was performed based on study type (retrospective and prospective), race (Asians and Caucasians) and sample type (tissue and plasma). RESULTS: A total of 25 studies involving 1,770 patients were included. The overall T790M existent rate was 45.25%. Post-resistance T790M was more frequent in 19 del than in L858R mutated patients (53% vs. 36%; OR 1.87; P<0.001). All outcomes of subgroup and overall analyses were similar. In contrast, we re-analyzed the previous meta-analysis, finding that the pooled rate of pretreatment T790M was 14% and 22% in 19 del and L858R respectively (OR 0.59; P<0.001). The increase of T790M rate was 2.79-fold in 19 del and only 0.63-fold in L858R in the course of EGFR-TKIs therapy. CONCLUSIONS: Opposite to the situation of de novo T790M, it was observed that T790M was more frequent in exon 19 deletion than in L858R among patients with acquired resistance to EGFR-TKIs. The difference in T790M alteration between 19 del and L858R encourages development of detection or treatment strategies for the specific resistance mechanism.
BACKGROUND: Treatment-naive epidermal growth factor receptor (EGFR) T790M mutation is more inclined to coexist with L858R than with 19 del in non-small cell lung cancer (NSCLC) patients. However, EGFR-tyrosine kinase inhibitors (EGFR-TKIs) might alter this status. We sought to compare the prevalence of T790M upon acquired resistance to EGFR-TKIs between 19 del and L858R by assembling all existing data. METHODS: Electronic databases were comprehensively searched for eligible studies. The primary endpoint was the odds ratio (OR) of T790M mutation in NSCLC co-existing with L858R mutation and 19 del upon resistance to first-generation EGFR-TKIs. A random effects model was used. Stratified analysis was performed based on study type (retrospective and prospective), race (Asians and Caucasians) and sample type (tissue and plasma). RESULTS: A total of 25 studies involving 1,770 patients were included. The overall T790M existent rate was 45.25%. Post-resistance T790M was more frequent in 19 del than in L858R mutated patients (53% vs. 36%; OR 1.87; P<0.001). All outcomes of subgroup and overall analyses were similar. In contrast, we re-analyzed the previous meta-analysis, finding that the pooled rate of pretreatment T790M was 14% and 22% in 19 del and L858R respectively (OR 0.59; P<0.001). The increase of T790M rate was 2.79-fold in 19 del and only 0.63-fold in L858R in the course of EGFR-TKIs therapy. CONCLUSIONS: Opposite to the situation of de novo T790M, it was observed that T790M was more frequent in exon 19 deletion than in L858R among patients with acquired resistance to EGFR-TKIs. The difference in T790M alteration between 19 del and L858R encourages development of detection or treatment strategies for the specific resistance mechanism.
Authors: Juliann Chmielecki; Jasmine Foo; Geoffrey R Oxnard; Katherine Hutchinson; Kadoaki Ohashi; Romel Somwar; Lu Wang; Katherine R Amato; Maria Arcila; Martin L Sos; Nicholas D Socci; Agnes Viale; Elisa de Stanchina; Michelle S Ginsberg; Roman K Thomas; Mark G Kris; Akira Inoue; Marc Ladanyi; Vincent A Miller; Franziska Michor; William Pao Journal: Sci Transl Med Date: 2011-07-06 Impact factor: 17.956
Authors: Noemi Reguart; Rafael Rosell; Felipe Cardenal; Andres F Cardona; Dolores Isla; Ramon Palmero; Teresa Moran; Christian Rolfo; M Cinta Pallarès; Amelia Insa; Enric Carcereny; Margarita Majem; Javier De Castro; Cristina Queralt; Miguel A Molina; Miquel Taron Journal: Lung Cancer Date: 2014-03-02 Impact factor: 5.705
Authors: Wonjun Ji; Chang-Min Choi; Jin Kyung Rho; Se Jin Jang; Young Soo Park; Sung-Min Chun; Woo Sung Kim; Jung-Shin Lee; Sang-We Kim; Dae Ho Lee; Jae Cheol Lee Journal: BMC Cancer Date: 2013-12-27 Impact factor: 4.430
Authors: Ying Jin; Hua Bao; Xiuning Le; Xiaojun Fan; Ming Tang; Xun Shi; Jun Zhao; Junrong Yan; Yang Xu; Kelly Quek; Yasir Y Elamin; Jianhua Zhang; P Andrew Futreal; Ignacio I Wistuba; John V Heymach; Guangyuan Lou; Lan Shao; Qiong He; Chen Lin; Xue Wu; Yang W Shao; Xiaonan Wang; Jiachen He; Yamei Chen; Justin Stebbing; Ming Chen; Jianjun Zhang; Xinmin Yu Journal: Oncogene Date: 2019-11-21 Impact factor: 9.867